bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
092-10-0019

Order Name:
CYP2C19 genotyping (3 SNP; Fast track)

 
Useful For:
Identifying patients who may be at risk for altered metabolism of drugs that are modified by CYP2C19. Predicting drug response to antiplatelet (Clopidogrel/Plavix), proton pump inhibitors, antidepressants, antimalarial drugs, anticonvulsants, b-adrenergic blockers and antifungal (voriconazole).
 
Methodology:
Real-time PCR
 
AliasesName:
CYP2C19
pgx
Pharmacogenetics
Pharmacogenomics
 
 
 
Test Code:
092-10-0019

Order Name:
CYP2C19 genotyping (3 SNP; Fast track)

 
Collection Specimen Or Container:
Blood/ K3 EDTA (K3E) (Lavender Top) 3 mL, 1 tube
 
Specimen Testing Type:
Whole blood, K3 EDTA (K3E) (Lavender Top) 3 mL, 1 tube, minimum volume 1.5 ml
 
Sub Mission Container:
Original tube
 
Rejection Criteria:
Use heparin as anticoagulant, Severe clotted specimen will be reject.
 
Specimen Stabillity:
Specimen Type Temperature Time
EDTA Whole Blood Refrigerated, 2oC to 8oC 7 days
 
 
 
Test Code:
092-10-0019

Order Name:
CYP2C19 genotyping (3 SNP; Fast track)

 
Method detail:
Real-time PCR
 
Schedule:
Test Daily
 
Turnaround Time:
Received specimen to report within 3 days
 
Performing Location:
Research and Development, Tel. 14252
 
Specimen Retention Time:
3 months
 
 
 
Test Code:
092-10-0019

Order Name:
CYP2C19 genotyping (3 SNP; Fast track)

 
 
Clinical Information:
CYP2C19 is an important drug metabolizing enzyme that catalyzes the biotransformation of many other clinically useful drugs including selective serotonin reuptake inhibitors (SSRI), tricyclic antidepressants, clopidogrel, voriconazole, and proton pump inhibitors. This test identifies four common alleles (*1, *2, *3, *17) by Real-time PCR. The CYP2C19 genotyping (3 SNP; Fast track) test covers two known no functional alleles and one known rapid functional allele. 
 
Clinical Reference:
  1. Scott SA, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22.
  2. Pratt VM, et al. Recommendations for Clinical CYP2C19 Genotyping Allele Selection: A Report of the Association for Molecular Pathology. J Mol Diagn. 2018 May;20(3):269-276. doi: 10.1016/j.jmoldx.2018.01.011. Epub 2018 Feb 21.